ESTRO 38 Abstract book

S769 ESTRO 38

Folfirinox (four cycles every 14 days). Patients without disease progression after restaging received conformal radiation therapy with concurrent gemcitabine at the dose of 600 mg/mq weekly.

To describe local control, overall survival, progression- free survival and toxicities of Cyberknife® based stereotactic body radiation therapy (SBRT) in the treatment of hepatocellular carcinoma (HCC). Material and Methods The records of all the patients treated for HCC at the Eugene Marquis center, Rennes and the Bretonneau Hospital, Tours; between November 2010 and December 2016, were reviewed. The treatment was performed as a salvage treatment; as a bridge to liver transplantation or if no other treatment was possible. Results 136 patients were consecutively included in the study. The median follow-up was 13 months. The median total dose prescribed, median fractionation and median overall treatment time were respectively 45 Gy, 3 fractions and 5 days. The overall survival, progression-free survival and local control rates at 1 year and 2 years were 79.8% and 63.5%; 61.3% and 39.4%; 94.5% and 91%.. Two grade 3 acute toxicity events and two grade 4 late toxicity events corresponding to a duodenal ulcer have been reported. Seven patients underwent classic RILD (radio-induced hepatitis) and thirteen patients showed non-classical RILD. BCLC stage, WHO grade and PTV volume were correlated with overall survival in univariate Cox analysis.

Results Further to the results of the pre-treatment workup, nine patients (40,9%) were excluded from the protocol because of the evidence of metastatic disease, and thus a total of thirteen patients were consequently enrolled. Five patients (38,5%) had a progression of disease after induction chemotherapy. Eight patients (61,5%) completed radiochemotherapy. Of these, four patients underwent surgical radical resection (30,8%). At the present, the median Overall Survival was 13,8 months and the median Progression Free Survival was 18,9 months. For the entire cohort of patients the treatment was well tolerated. Only haematological grade 3-4 toxicities were observed. Conclusion Altough the follow-up time is limited, these preliminary data of theprotocol treatment show promising results for patients with borderline resectable and unresectable pancreatic cancer. The enrollment is actually ongoing. Continued optimization in multimodality therapy and an accurate patient selection are crucial for the appropriate treatment of patients. EP-1416 Palliative Oesophageal Chemoradiotherapy: A Phase 1 Clinical Trial J. Martin 1 , D. Fiona 2 , J. Loh 3 , S. Ackland 2 , T. Bonaventura 2 , M. Fay 1 , M. Kumar 1 , J. Lynam 2 , G. Mallesara 2 , M. O'Neill 1 , J. Smart 1 , A. Van der Westhuizen 2 , V. Wills 4 , T. Wright 4 1 Calvary Mater Newcastle, Radiation Oncology, Newcastle- NSW, Australia ; 2 Calvary Mater Newcastle, Medical Oncology, Newcastle- NSW, Australia ; 3 University of Malaya, Radiation Oncology, Kuala Lumpur, Malaysia ; 4 John Hunter Hospital, Department of Surgery, Newcastle- NSW, Australia Purpose or Objective Optimal palliative treatment of metastatic oesophageal carcinoma with dysphagia (OesC) is controversial. Competing risks include treatment toxicity, treatment duration, symptom management and disease control. We explore a potentially better tolerated chemoradiotherapy (CRT) regimen in a carefully selected patient cohort. This abstract is part of the media pr gramme a d will be released on the day of its presentation

Conclusion SBRT is an effective and well tolerated in the treatment of inoperable HCC or as a bridge to liver transplantation. The toxicity is mainly related to cirrhotic background and requires a selection of patients and strict dose constraints. EP-1415 Preliminary results of a phase II study of induction Folfirinox followed by chemoradiation in LAPC P. Trecca 1 , M. Fiore 1 , R. Coppola 2 , L.E. Trodella 1 , R.M. D'Angelillo 1 , L. Trodella 1 , S. Ramella 1 1 Campus-Bio Medico University, Radiotherapy Unit, Rome, Italy ; 2 Campus-Bio Medico University, General Surgery, Rome, Italy Purpose or Objective The aim of this study was to evaluate the safety and efficacy of induction FOLFIRINOX followed by a high weekly dose of gemcitabine-based radiochemotherapy in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Material and Methods This trial was performed as a single-center one-armed phase II study. From January 2015 we evaluated twenty- two patients with borderline resectable or unresectable pancreatic cancer (characteristics of patients are summarized in table 1). A pre-treatment staging was performed with CT scan, 18FDG PET-CT scan and laparoscopy. Patients with metastatic disease were excluded. Suitable patients received chemotherapy with